These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Advances in the delivery of RNA therapeutics: from concept to clinical reality. Kaczmarek JC; Kowalski PS; Anderson DG Genome Med; 2017 Jun; 9(1):60. PubMed ID: 28655327 [TBL] [Abstract][Full Text] [Related]
3. Critical issues in delivery of RNAi therapeutics in vivo. Rivera S; Yuan F Curr Pharm Biotechnol; 2012 Jun; 13(7):1279-91. PubMed ID: 22201583 [TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacology of RNA Interference-Based Therapeutics: A Summary Based on Food and Drug Administration-Approved Small Interfering RNAs. Jing X; Arya V; Reynolds KS; Rogers H Drug Metab Dispos; 2023 Feb; 51(2):193-198. PubMed ID: 36332914 [TBL] [Abstract][Full Text] [Related]
8. RNA therapeutics: updates and future potential. Zhang C; Zhang B Sci China Life Sci; 2023 Jan; 66(1):12-30. PubMed ID: 36100838 [TBL] [Abstract][Full Text] [Related]
9. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. Mahato RI; Cheng K; Guntaka RV Expert Opin Drug Deliv; 2005 Jan; 2(1):3-28. PubMed ID: 16296732 [TBL] [Abstract][Full Text] [Related]
10. Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug. Debacker AJ; Voutila J; Catley M; Blakey D; Habib N Mol Ther; 2020 Aug; 28(8):1759-1771. PubMed ID: 32592692 [TBL] [Abstract][Full Text] [Related]
11. DNA-based therapeutics and DNA delivery systems: a comprehensive review. Patil SD; Rhodes DG; Burgess DJ AAPS J; 2005 Apr; 7(1):E61-77. PubMed ID: 16146351 [TBL] [Abstract][Full Text] [Related]
12. Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System. Mendonça MCP; Kont A; Aburto MR; Cryan JF; O'Driscoll CM Mol Pharm; 2021 Apr; 18(4):1491-1506. PubMed ID: 33734715 [TBL] [Abstract][Full Text] [Related]
13. Nucleic acid delivery for therapeutic applications. Gupta A; Andresen JL; Manan RS; Langer R Adv Drug Deliv Rev; 2021 Nov; 178():113834. PubMed ID: 34492233 [TBL] [Abstract][Full Text] [Related]
14. [Study toward practical use of oligonucleotide therapeutics]. Inoue T; Yoshida T Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):13-5. PubMed ID: 25707197 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Deng Y; Wang CC; Choy KW; Du Q; Chen J; Wang Q; Li L; Chung TK; Tang T Gene; 2014 Apr; 538(2):217-27. PubMed ID: 24406620 [TBL] [Abstract][Full Text] [Related]
17. Delivery of small interfering RNA. A review and an example of application to a junction oncogene. Ramon AL; Bertrand JR; Malvy C Tumori; 2008; 94(2):254-63. PubMed ID: 18564614 [TBL] [Abstract][Full Text] [Related]
18. Antisense technology: an emerging platform for cardiovascular disease therapeutics. Lee RG; Crosby J; Baker BF; Graham MJ; Crooke RM J Cardiovasc Transl Res; 2013 Dec; 6(6):969-80. PubMed ID: 23856914 [TBL] [Abstract][Full Text] [Related]
19. Liver as a target for oligonucleotide therapeutics. Sehgal A; Vaishnaw A; Fitzgerald K J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039 [TBL] [Abstract][Full Text] [Related]